Literature DB >> 15177480

Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.

Hong-yu Li1, Yan Wang, Lei Yan, Robert M Campbell, Bryan D Anderson, Jill R Wagner, Jonathan M Yingling.   

Abstract

A novel series of 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines was synthesized and their TbetaR-1 inhibitory, p38 MAPK inhibitory, and TbetaR-1-dependent cellular activity were evaluated. Compound 5a was found to be a highly potent in the enzyme assay and TbetaR-1-dependent cellular assays. In addition, dimer (4g), with a urea linker, shows a similar enzyme and cellular activity despite a bulky substitution.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177480     DOI: 10.1016/j.bmcl.2004.04.065

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Peptide ligands that use a novel binding site to target both TGF-β receptors.

Authors:  Lingyin Li; Brendan P Orner; Tao Huang; Andrew P Hinck; Laura L Kiessling
Journal:  Mol Biosyst       Date:  2010-10-04

2.  Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.

Authors:  Juan Sepulveda-Sanchez; Ana Ramos; Amaya Hilario; Guillermo DE Velasco; Daniel Castellano; Marta Garcia DE LA Torre; Jordi Rodon; Michael F Lahn
Journal:  Oncol Lett       Date:  2015-04-08       Impact factor: 2.967

3.  Small molecule antagonists of the TGF-beta1/TGF-beta receptor binding interaction.

Authors:  James K Burmester; Sherry A Salzman; Kai Qi Zhang; Richard A Dart
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.

Authors:  Armin Maier; Anne-Lise Peille; Vincent Vuaroqueaux; Michael Lahn
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

Review 5.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

Authors:  Stephan Herbertz; J Scott Sawyer; Anja J Stauber; Ivelina Gueorguieva; Kyla E Driscoll; Shawn T Estrem; Ann L Cleverly; Durisala Desaiah; Susan C Guba; Karim A Benhadji; Christopher A Slapak; Michael M Lahn
Journal:  Drug Des Devel Ther       Date:  2015-08-10       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.